Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
PaperCitations, authors & open-access status
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 59 citations, 2022 year and diamond oa status.
59
Citations
2022
Year
diamond
OA Status